ERBB2 and neoplasm: Heterogeneity of HER2 IHC staining was noted in around 50% of cases as demonstrated by variability in intratumoral HER2 overexpression (i.e., ≤ 30% of tumor cells exhibiting staining) with greater heterogeneity in lower IHC staining categories [16].